APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Targeting Biological Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IL-17 Targeting Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025182 pages

Choose your research edition.

Industry ResearchIL-17 Targeting Biological Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Targeting Biological Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal IL-17 Targeting Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Targeting Biological Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Targeting Biological Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global IL-17 Targeting Biological Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IL-17 Targeting Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-17 Targeting Biological Drugs include AstraZeneca, DICE Therapeutics, Eli Lilly and Co., Novartis, UCB, Jiangsu Hengrui Medicine, Akesobio and Chongqing Genrix Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-17 Targeting Biological Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-17 Targeting Biological Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-17 Targeting Biological Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-17 Targeting Biological Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-17 Targeting Biological Drugs Segment by Company

AstraZeneca

DICE Therapeutics

Eli Lilly and Co.

Novartis

UCB

Jiangsu Hengrui Medicine

Akesobio

Chongqing Genrix Biopharmaceutical

IL-17 Targeting Biological Drugs Segment by Type

Oral

Injection

IL-17 Targeting Biological Drugs Segment by Application

Hospital

Clinic

Other

IL-17 Targeting Biological Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Targeting Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Targeting Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Targeting Biological Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-17 Targeting Biological Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-17 Targeting Biological Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IL-17 Targeting Biological Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IL-17 Targeting Biological Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IL-17 Targeting Biological Drugs Industry Trends Table 2. IL-17 Targeting Biological Drugs Industry Drivers Table 3. IL-17 Targeting Biological Drugs Industry Opportunities and Challenges Table 4. IL-17 Targeting Biological Drugs Industry Restraints Table 5. Global IL-17 Targeting Biological Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IL-17 Targeting Biological Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IL-17 Targeting Biological Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IL-17 Targeting Biological Drugs Sales Market Share by Manufacturers Table 9. Global IL-17 Targeting Biological Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IL-17 Targeting Biological Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IL-17 Targeting Biological Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IL-17 Targeting Biological Drugs Manufacturers, Product Type & Application Table 13. Global IL-17 Targeting Biological Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-17 Targeting Biological Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Global IL-17 Targeting Biological Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global IL-17 Targeting Biological Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global IL-17 Targeting Biological Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global IL-17 Targeting Biological Drugs Sales Market Share by Type (2021-2026) Table 22. Global IL-17 Targeting Biological Drugs Sales Market Share by Type (2027-2032) Table 23. Global IL-17 Targeting Biological Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global IL-17 Targeting Biological Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global IL-17 Targeting Biological Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global IL-17 Targeting Biological Drugs Revenue Market Share by Type (2021-2026) Table 27. Global IL-17 Targeting Biological Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global IL-17 Targeting Biological Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global IL-17 Targeting Biological Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global IL-17 Targeting Biological Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global IL-17 Targeting Biological Drugs Sales Market Share by Application (2021-2026) Table 35. Global IL-17 Targeting Biological Drugs Sales Market Share by Application (2027-2032) Table 36. Global IL-17 Targeting Biological Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global IL-17 Targeting Biological Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global IL-17 Targeting Biological Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global IL-17 Targeting Biological Drugs Revenue Market Share by Application (2021-2026) Table 40. Global IL-17 Targeting Biological Drugs Revenue Market Share by Application (2027-2032) Table 41. Global IL-17 Targeting Biological Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global IL-17 Targeting Biological Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global IL-17 Targeting Biological Drugs Sales Market Share by Region (2021-2026) Table 44. Global IL-17 Targeting Biological Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global IL-17 Targeting Biological Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America IL-17 Targeting Biological Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America IL-17 Targeting Biological Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe IL-17 Targeting Biological Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe IL-17 Targeting Biological Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific IL-17 Targeting Biological Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific IL-17 Targeting Biological Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global IL-17 Targeting Biological Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global IL-17 Targeting Biological Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global IL-17 Targeting Biological Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global IL-17 Targeting Biological Drugs Revenue Market Share by Region (2021-2026) Table 62. Global IL-17 Targeting Biological Drugs Revenue Market Share by Region (2027-2032) Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AstraZeneca IL-17 Targeting Biological Drugs Product Portfolio Table 67. AstraZeneca Recent Development Table 68. DICE Therapeutics Company Information Table 69. DICE Therapeutics Business Overview Table 70. DICE Therapeutics IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. DICE Therapeutics IL-17 Targeting Biological Drugs Product Portfolio Table 72. DICE Therapeutics Recent Development Table 73. Eli Lilly and Co. Company Information Table 74. Eli Lilly and Co. Business Overview Table 75. Eli Lilly and Co. IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Eli Lilly and Co. IL-17 Targeting Biological Drugs Product Portfolio Table 77. Eli Lilly and Co. Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis IL-17 Targeting Biological Drugs Product Portfolio Table 82. Novartis Recent Development Table 83. UCB Company Information Table 84. UCB Business Overview Table 85. UCB IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. UCB IL-17 Targeting Biological Drugs Product Portfolio Table 87. UCB Recent Development Table 88. Jiangsu Hengrui Medicine Company Information Table 89. Jiangsu Hengrui Medicine Business Overview Table 90. Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Product Portfolio Table 92. Jiangsu Hengrui Medicine Recent Development Table 93. Akesobio Company Information Table 94. Akesobio Business Overview Table 95. Akesobio IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Akesobio IL-17 Targeting Biological Drugs Product Portfolio Table 97. Akesobio Recent Development Table 98. Chongqing Genrix Biopharmaceutical Company Information Table 99. Chongqing Genrix Biopharmaceutical Business Overview Table 100. Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Product Portfolio Table 102. Chongqing Genrix Biopharmaceutical Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. IL-17 Targeting Biological Drugs Distributors List Table 106. IL-17 Targeting Biological Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. IL-17 Targeting Biological Drugs Product Image Figure 2. Global IL-17 Targeting Biological Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Targeting Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-17 Targeting Biological Drugs Sales (2021-2032) & (K Units) Figure 5. Global IL-17 Targeting Biological Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IL-17 Targeting Biological Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global IL-17 Targeting Biological Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global IL-17 Targeting Biological Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global IL-17 Targeting Biological Drugs Sales Market Share by Type (2021-2032) Figure 13. Global IL-17 Targeting Biological Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global IL-17 Targeting Biological Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global IL-17 Targeting Biological Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global IL-17 Targeting Biological Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global IL-17 Targeting Biological Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global IL-17 Targeting Biological Drugs Sales Market Share by Application (2021-2032) Figure 22. Global IL-17 Targeting Biological Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global IL-17 Targeting Biological Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global IL-17 Targeting Biological Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America IL-17 Targeting Biological Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe IL-17 Targeting Biological Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific IL-17 Targeting Biological Drugs Sales Market Share by Country (2021-2032) Figure 39. China IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile IL-17 Targeting Biological Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global IL-17 Targeting Biological Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global IL-17 Targeting Biological Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America IL-17 Targeting Biological Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe IL-17 Targeting Biological Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific IL-17 Targeting Biological Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa IL-17 Targeting Biological Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. IL-17 Targeting Biological Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. IL-17 Targeting Biological Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • AstraZeneca
  • DICE Therapeutics
  • Eli Lilly and Co.
  • Novartis
  • UCB
  • Jiangsu Hengrui Medicine
  • Akesobio
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IL-17 Targeting Biological Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IL-17 Targeting Biological Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IL-17 Targeting Biological Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IL-17 Targeting Biological Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IL-17 Targeting Biological Drugs Market Dynamics
  1. 2.1 IL-17 Targeting Biological Drugs Industry Trends
  2. 2.2 IL-17 Targeting Biological Drugs Industry Drivers
  3. 2.3 IL-17 Targeting Biological Drugs Industry Opportunities and Challenges
  4. 2.4 IL-17 Targeting Biological Drugs Industry Restraints
3 IL-17 Targeting Biological Drugs Market by Manufacturers
  1. 3.1 Global IL-17 Targeting Biological Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IL-17 Targeting Biological Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global IL-17 Targeting Biological Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IL-17 Targeting Biological Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-17 Targeting Biological Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IL-17 Targeting Biological Drugs Manufacturers, Product Type & Application
  7. 3.7 Global IL-17 Targeting Biological Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-17 Targeting Biological Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-17 Targeting Biological Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-17 Targeting Biological Drugs Tier 1, Tier 2, and Tier 3
4 IL-17 Targeting Biological Drugs Market by Type
  1. 4.1 IL-17 Targeting Biological Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global IL-17 Targeting Biological Drugs Sales by Type
  5. 4.2.1 Global IL-17 Targeting Biological Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global IL-17 Targeting Biological Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global IL-17 Targeting Biological Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global IL-17 Targeting Biological Drugs Revenue by Type
  9. 4.3.1 Global IL-17 Targeting Biological Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global IL-17 Targeting Biological Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global IL-17 Targeting Biological Drugs Revenue Market Share by Type (2021-2032)
5 IL-17 Targeting Biological Drugs Market by Application
  1. 5.1 IL-17 Targeting Biological Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Targeting Biological Drugs Sales by Application
  6. 5.2.1 Global IL-17 Targeting Biological Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Targeting Biological Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global IL-17 Targeting Biological Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global IL-17 Targeting Biological Drugs Revenue by Application
  10. 5.3.1 Global IL-17 Targeting Biological Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IL-17 Targeting Biological Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global IL-17 Targeting Biological Drugs Revenue Market Share by Application (2021-2032)
6 Global IL-17 Targeting Biological Drugs Sales by Region
  1. 6.1 Global IL-17 Targeting Biological Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-17 Targeting Biological Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IL-17 Targeting Biological Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global IL-17 Targeting Biological Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IL-17 Targeting Biological Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IL-17 Targeting Biological Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IL-17 Targeting Biological Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IL-17 Targeting Biological Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IL-17 Targeting Biological Drugs Revenue by Region
  1. 7.1 Global IL-17 Targeting Biological Drugs Revenue by Region
  2. 7.1.1 Global IL-17 Targeting Biological Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IL-17 Targeting Biological Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global IL-17 Targeting Biological Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global IL-17 Targeting Biological Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IL-17 Targeting Biological Drugs Revenue (2021-2032)
  8. 7.2.2 North America IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IL-17 Targeting Biological Drugs Revenue (2021-2032)
  11. 7.3.2 Europe IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IL-17 Targeting Biological Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IL-17 Targeting Biological Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IL-17 Targeting Biological Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca IL-17 Targeting Biological Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 DICE Therapeutics
  8. 8.2.1 DICE Therapeutics Company Information
  9. 8.2.2 DICE Therapeutics Business Overview
  10. 8.2.3 DICE Therapeutics IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 DICE Therapeutics IL-17 Targeting Biological Drugs Product Portfolio
  12. 8.2.5 DICE Therapeutics Recent Developments
  13. 8.3 Eli Lilly and Co.
  14. 8.3.1 Eli Lilly and Co. Company Information
  15. 8.3.2 Eli Lilly and Co. Business Overview
  16. 8.3.3 Eli Lilly and Co. IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Co. IL-17 Targeting Biological Drugs Product Portfolio
  18. 8.3.5 Eli Lilly and Co. Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis IL-17 Targeting Biological Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 UCB
  26. 8.5.1 UCB Company Information
  27. 8.5.2 UCB Business Overview
  28. 8.5.3 UCB IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 UCB IL-17 Targeting Biological Drugs Product Portfolio
  30. 8.5.5 UCB Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine IL-17 Targeting Biological Drugs Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Akesobio
  38. 8.7.1 Akesobio Company Information
  39. 8.7.2 Akesobio Business Overview
  40. 8.7.3 Akesobio IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Akesobio IL-17 Targeting Biological Drugs Product Portfolio
  42. 8.7.5 Akesobio Recent Developments
  43. 8.8 Chongqing Genrix Biopharmaceutical
  44. 8.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 8.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 8.8.3 Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chongqing Genrix Biopharmaceutical IL-17 Targeting Biological Drugs Product Portfolio
  48. 8.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-17 Targeting Biological Drugs Value Chain Analysis
  2. 9.1.1 IL-17 Targeting Biological Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-17 Targeting Biological Drugs Production Mode & Process
  6. 9.2 IL-17 Targeting Biological Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-17 Targeting Biological Drugs Distributors
  9. 9.2.3 IL-17 Targeting Biological Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst